The parallel distributor informed its supplied customers on June 4, 2014 and asked for a stock check of the affected batches.

In a letter dated May 26, 2014, the marketing authorization holder informed its customers that the degree of discoloration of batch 2G605A is just outside the permitted limit and the impurities are elevated. For batch 2M631A, although the degree of…

The marketing authorization holder has informed its supplied customers by letter dated 21.05.2014 that the above batch is being recalled as a precautionary measure due to possible particles.

The marketing authorization holder informed its supplied customers by letter dated April 24, 2014, that due to the implementing decision C(2013)9846 in the context of the European risk assessment procedure according to Article 31 of Directive…

The marketing authorization holder informed its supplied customers by letter dated April 28, 2014, that due to the implementing decision C (2013)9846 in the context of the European risk assessment procedure according to Article 31 of Directive…

The marketing authorization holder informed its supplied customers by letter dated April 28, 2014, that due to the implementing decision C(2013)9846 in the context of the European risk assessment procedure according to Article 31 Directive…

Questions and answers about the stolen vials of Herceptin and other affected products

The distribution company informed its supplied customers on April 18, 2014 and asked for a stock check of the affected batches.

The parallel distributor has informed its supplied customers in a letter dated 18.04.2014 that Herceptin in Italian presentation has been adulterated and introduced into the legal distribution chain. Therefore, a recall of the above mentioned Italian…

Update from the European Medicines Agency on stolen vials of Herceptin and other affected products